Lung CancerTEALSNCT04948060
Tribally Engaged Approaches to Lung Screening (TEALS)
A study testing Enhanced lung cancer screening services in people with Lung Cancer, run by University of Oklahoma at 1 site in United States.
Trial summary
Lung cancer is the leading cause of cancer mortality among American Indians and Alaska Natives (AI/AN), and AI/AN have worse lung cancer incidence rates, survival, and death compared to the general population. Read more about this study
- Who is it for?
- Ages 50 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Lung Cancer
- What is being tested?
- Enhanced lung cancer screening services
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 275 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jan 2022to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- adults aged 50-80
- 30 pack-year smoking history
- currently smoke or quit in the past 15 years.
Who cannot join
- Those who are not willing to be screened or followed up with diagnostic testing or intervention, if positive.
- Those who are otherwise designated by their primary care doctors as not able to benefit from screening.
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
About this study
Lung cancer is the leading cause of cancer mortality among American Indians and Alaska Natives (AI/AN), and AI/AN have worse lung cancer incidence rates, survival, and death compared to the general population. Because lung cancer screening (LCS) with low-dose computed tomography (LDCT) has been shown to reduce lung cancer mortality by roughly 20%, the United States Preventive Services Task Force now recommends LCS for men and women aged 55-80 years who meet specific eligibility criteria (grade-B evidence), and subsequently the Center for Medicare and Medicaid Services (CMS) opted to cover this test. However, the uptake of LCS implementation has been slow in most healthcare systems, and LCS implementation among AI/AN has never been studied.
To address this knowledge, we prose the "Tribally Engaged Approaches to Lung Screening (TEALS)" study, which is a collaborative effort between the Choctaw Nation of Oklahoma, the Stephenson Cancer Center, and the University of Oklahoma Health Sciences Center.
Read more
Over the course of 5 years, TEALS will:
- Conduct focus groups and semi-structured interviews with CNHSA patients, clinicians, and health administrators to elucidate individual- and system-level barriers and facilitators that affect the implementation of LCS;
- Develop an LCS care coordination intervention that will identify eligible persons for LCS, help these patients navigate the screening process, and link them with smoking cessation services, when applicable;
- Measure the impact of the TEALS intervention on the receipt of screening and a set of patient- and practice-level outcomes by conducting a cluster-randomized clinical trial of LCS implementation; and
- Disseminate the TEALS program to other researchers and healthcare systems that serve AI/AN patients. TEALS will bridge the gap between evidence and clinical practice for LCS in a high-need, low-resource setting by intervening at the level of the healthcare system.
System-level interventions for guideline implementation tend to be understudied compared to those evaluating individual-level, behavioral interventions. However, the careful development and evaluation of an LCS screening program at the level of the healthcare system would be critical to ensure that more patients can receive LCS. Our research will create a critically needed platform from which future studies could be launched that will examine how to tailor the application of the LCS guideline to the individual preferences of AI/AN patients.
TEALS will establish an effective LCS program in a tribal system and thus provide a direct benefit to the Choctaw Nation by increasing LCS participation. TEALS will serve as a blueprint for establishing a sustainable and accessible infrastructure for LCS in AI/AN and other community health systems. By increasing screening for early stage lung cancer, TEALS could ultimately reduce lung cancer mortality in AI/AN communities.
Read the detailed description
Lung cancer screening (LCS) with low-dose computed tomography (LDCT) reduces mortality from lung cancer and it is recommended by the United States Preventive Services Task Force (USPSTF) based on grade-B evidence, 1 the same grade of evidence given by the USPSTF for breast cancer screening with mammography. Lung cancer is the leading cause of cancer death among American Indians and Alaska Natives (AI/AN),2-4 who face persistent disparities in lung cancer incidence, stage of diagnosis, stage-specific survival, and death compared to Whites, particularly in the Plains states and Alaska.2,3,5-14 Early detection of lung cancer at less lethal stages would have a significant impact on improving the health of Native Americans by reducing their lung cancer mortality. In addition to detection and treatment, smoking cessation is also pivotal to improving lung cancer outcomes.
LCS implementation at the healthcare system level is complex15 and uptake has been slow for the general population, particularly in community settings. System-level implementation may be even more complex in AI/AN communities, which are often characterized by distinctive community, cultural, and health system factors. Community-based participatory research, founded on a partnership approach to research that involves community members, organizational representatives, and researchers in all aspects of the research process,16 has improved research partnerships with AI/AN communities,17 including cancer related research.18-22 Moreover, dissemination and implementation (D\&I) science23-25 has been highly effective in redesigning care delivery systems to improve the uptake of preventive services,25 but has received scant attention in LCS implementation or in AI/AN communities. Coupling the principles of participatory research with D\&I science holds great promise for developing a durable and novel LCS program that responds to the needs of patients, communities, and healthcare systems.
The Choctaw Nation, the third largest tribe in the nation by population, is located in rural southeastern Oklahoma. The advent of the LCS guideline prompted the tribe to name LCS as a top priority for its own, tribally operated healthcare system, the Choctaw Nation Health Services Authority (CNHSA). An ensuing partnership-based consultation over the past several years between CNHSA staff and university researchers with expertise in D\&I science, led to the present study entitled "Tribally Engaged Approaches to Lung Screening (TEALS)". The goal of TEALS is to collaboratively co-develop, implement and evaluate a sustainable and community-centered LCS implementation program that can be disseminated to other tribal health systems.
Our specific aims are to:
Aim 1. Identify individual, community, cultural, and health system barriers and facilitators that affect LCS implementation in the Choctaw Nation. During Year 1, the investigators will convene focus groups and administer semi-structured interviews with key stakeholders (tribal members receiving care through CNHSA, tribal community leaders, clinicians, and health administrators) to elucidate individual, tribal, cultural and health system factors that may critically affect the uptake of LCS. The investigators will incorporate our findings into the TEALS intervention protocols and materials.
Aim 2. Use community-engagement processes to co-design a tailored TEALS intervention, which features LCS care coordinators embedded within the CNHSA healthcare delivery system. In Year 2, informed by Aim 1 findings, the investigators will finalize the TEALS intervention, and then pilot test, evaluate, and iteratively improve it in two CNHSA primary care practices.
Aim 3. Measure the impact of the improved LCS program in a cluster-randomized clinical trial, assessing implementation process outcomes at the individual and care delivery system level. In Years 3 and 4, the investigators will conduct a pair-matched, cluster-randomized implementation trial of the LCS program in three control and three intervention primary care CNHSA practices. The investigators hypothesize that a significantly higher proportion of LCS-eligible patients in the intervention group will receive LCS, and significantly more LCS participants who smoke cigarettes in the intervention group will be referred for smoking cessation advice, compared to the control group.
Aim 4. Disseminate the LCS program to other health systems serving AI/AN patients. In Year 5, the investigators will work closely with Choctaw Nation and other AI/AN-serving health system stakeholders in Oklahoma and other US locations to disseminate the TEALS program in order to facilitate the replication of the program in other settings.
Our team shares the commitment to engage in research that is of direct benefit to AI/AN communities. The national rate of LCS with low-dose CT was only 3.9% in 2015, 26 making this project particularly timely and relevant. TEALS will provide immediate benefit in rates of lung cancer screening for the Choctaw Nation, and has the ultimate goal of reducing lung cancer mortality by widespread implementation of LCS in health systems serving AI/AN communities. TEALS has the novel feature of combining participatory approaches with implementation science to create one of the first systematically designed and tribally run LCS programs in the country. Incorporating feedback from tribal community members and patients as well as healthcare professionals will enable an iterative adaptation of the TEALS intervention to the needs of healthcare systems serving Native people. Our participatory approach to D\&I science will provide an exemplary means of optimizing dissemination and implementation of LCS in other healthcare settings serving AI/AN patients.
- Conditions
- Lung Cancer
- Being tested
- Enhanced lung cancer screening services
- Keywords
- lung cancer, screening, early detection and treatment, primary care, implementation, community-engaged research, Native Americans, tribal health
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Enhanced lung cancer screening servicesOther
Also called LCS intervention
A theoretically sound and evidence-based, multi-component implementation strategy will be applied which includes care quality benchmarking and regular performance feedback, academic detailing provided by specially trained primary care clinicians, practice facilitation provided by trained and certified Practice Facilitators (PFs), health information technology (HIT) support, and facilitated professional networking to promote the cross-pollination and rapid dissemination of solutions and best practices in primary care settings
| Study group | Role | What they receive |
|---|---|---|
| Control 1-1 | Experimental | Patients and clinicians in control practices will receive usual Electronic Health Record (EHR) reminders for lung cancer screening (LCS). Receives: Other: Enhanced lung cancer screening services |
| Intervention 1-1 | Experimental | In addition to control group improvements, patients and clinicians in the intervention group will also receive an LCS Care Coordinator. Receives: Other: Enhanced lung cancer screening services |
| Control 1-2 | Experimental | Patients and Clinicians in control practices will have access to existing LCS services, smoking cessation, and lung cancer treatment services, but no additional system improvements will be introduced. Receives: Other: Enhanced lung cancer screening services |
| Intervention 1-2 | Experimental | In addition to control group improvements, patients and clinicians in the intervention group will also receive quality of care benchmarking and feedback academic detailing. Receives: Other: Enhanced lung cancer screening services |
| Intervention 1-3 | Experimental | In addition to control group improvements, patients and clinicians in the intervention group will also receive practice facilitation. Receives: Other: Enhanced lung cancer screening services |
| Intervention 1-4 | Experimental | In addition to control group improvements, patients and clinicians in the intervention group will also receive the opportunity to participate in a learning collaborative. Receives: Other: Enhanced lung cancer screening services |
| Intervention 1-5 | Experimental | In addition to control group improvements, patients and clinicians in the intervention group will also receive information technology support. Receives: Other: Enhanced lung cancer screening services |
What is being measured
The primary outcome is the main question the study is designed to answer.
1. Uptake of low-dose computed tomography lung cancer screening services
Receiving lung cancer screening (LCS) when eligible
Measured: 12 months
2. Uptake of low-dose computed tomography lung cancer screening services
Participating in a care planning visit with the lung-cancer screening coordinator (LCC) before screening and a follow-up visit, if screened positive
Measured: 12 months
3. Uptake of low-dose computed tomography lung cancer screening services
Receipt of follow-up treatment when clinically recommended
Measured: 12 months
4. Uptake of low-dose computed tomography lung cancer screening services
Receipt of smoking cessation intervention at any point of the LCS process.
Measured: 12 months
1. Health system-level care process outcomes
A RE-AIM framework will be utilized. Reach of the screening program will be measured by the proportion of LCS-eligible patients who were contacted by the screening coordinator
Measured: 12 months
2. Health system-level care process outcomes
A RE-AIM framework will be utilized. Effectiveness will be measured by the proportion of eligible patients who have completed the screening and treatment process according to their particular needs
Measured: 12 months
3. Health system-level care process outcomes
A RE-AIM framework will be utilized. Adoption will be measured by the proportion of individual clinician practices in the Choctaw Nation healthcare system that implemented the program.
Measured: 12 months
4. Health system-level care process intervention outcomes % of patients with LCS
A RE-AIM framework will be utilized. Implementation will be measured as the fidelity to the steps of the pre-determined LCS process in each practice
Measured: 12 months
5. Health system-level care process improvement outcomes
A RE-AIM framework will be utilized. Maintenance will be measured as the time of sustaining each LCS implementation key component at the practice and system level.
Measured: 12 months
Secondary outcomes (13)
Patient and health system-level scales
Socioeconomic scales
Measured: 12 months
CAHPS
Consumer Assessment of Healthcare Providers and Systems (CAHPS) PCC-10 scale
Measured: 12 months
PAM
Patient Activation Measure (PAM)-13 instrument
Measured: 12 months
CPCQ
Practice surveys will be conducted at the end of Year 3 and Year 4 and will be comprised of Change Process Capability Questionnaire (CPCQ)
Measured: 12 months
ACIC
Practice surveys will be conducted at the end of Year 3 and Year 4 and will be comprised Assessment of Chronic Illness Care (ACIC) scales that together provide a comprehensive measure of preventive care delivery system development.
Measured: 12 months
Qualitative measures of barriers and facilitators of patient participation in TEALS
Barriers and facilitators to patient participation in the TEALS program will be assessed thorough practice facilitator field observations.
Measured: 12 months
Qualitative measures of barriers and facilitators of patient participation in TEALS
Barriers and facilitators to patient participation in the TEALS program will be assessed thorough practice facilitation process notes.
Measured: 12 months
Qualitative measures of barriers and facilitators of patient participation in TEALS
Barriers and facilitators to patient participation in the TEALS program will be assessed thorough ongoing discussions with health system leaders.
Measured: 12 months
Qualitative measures of barriers and facilitators of patient participation in TEALS
Barriers and facilitators to patient participation in the TEALS program will be assessed thorough semi-structured interviews with patients, clinicians, and health system leaders.
Measured: 12 months
Qualitative measures of barriers and facilitators of practice participation in TEALS
Barriers and facilitators to practice participation in the TEALS program will be assessed thorough practice facilitator field observations.
Measured: 12 Months
Qualitative measures of barriers and facilitators of practice participation in TEALS
Barriers and facilitators to practice participation in the TEALS program will be assessed thorough practice facilitation process notes.
Measured: 12 Months
Qualitative measures of barriers and facilitators of practice participation in TEALS
Barriers and facilitators to practice participation in the TEALS program will be assessed thorough ongoing discussions with health system leaders.
Measured: 12 Months
Qualitative measures of barriers and facilitators of practice participation in TEALS
Barriers and facilitators to practice participation in the TEALS program will be assessed thorough semi-structured interviews with patients, clinicians, and health system leaders.
Measured: 12 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2021
- Study start1 Jan 2022
- Primary completion14 Jan 2023
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Pair-matched cluster-randomized controlled implementation trial with delayed intervention in the control group
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 275 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Oklahoma
- Sponsor type
- University, hospital or other
- Collaborators
- Choctaw Nation of Oklahoma
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04948060
- Sponsor's protocol ID
- 10187
- Acronym
- TEALS
- Status last verified
- Mar 2026
- First submitted
- 26 Apr 2021
- Last updated
- 1 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Sharing of IPD is strictly sanctioned by tribal health organizations. For this reason IPD will not be shared with entities not involved in the research activities.
Study at a glance
From the registry record, last updated by the sponsor on 1 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Tribally Engaged Approaches to Lung Screening (TEALS)
- ClinicalTrials.gov ID
- NCT04948060
- Acronym / sponsor ID
- TEALS / 10187
- Conditions
- Lung Cancer
- Keywords
- lung cancer, screening, early detection and treatment, primary care, implementation, community-engaged research, Native Americans, tribal health
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 275 participants (actual)
- Lead sponsor
- University of OklahomaUniversity, hospital or other
- Collaborators
- Choctaw Nation of Oklahoma
- Study start
- 1 Jan 2022 (actual)
- Primary completion
- 14 Jan 2023 (actual)
- Study completion
- Dec 2026 (estimated)
- First posted
- 1 Jul 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Lung cancer is the leading cause of cancer mortality among American Indians and Alaska Natives (AI/AN), and AI/AN have worse lung cancer incidence rates, survival, and death compared to the general population. Because lung cancer screening (LCS) with low-dose computed tomography (LDCT) has been shown to reduce lung cancer mortality by roughly 20%, the United States Preventive Services Task Force now recommends LCS for men and women aged 55-80 years who meet specific eligibility criteria (grade-B evidence), and subsequently the Center for Medicare and Medicaid Services (CMS) opted to cover this test. However, the uptake of LCS implementation has been slow in most healthcare systems, and LCS implementation among AI/AN has never been studied.
To address this knowledge, we prose the "Tribally Engaged Approaches to Lung Screening (TEALS)" study, which is a collaborative effort between the Choctaw Nation of Oklahoma, the Stephenson Cancer Center, and the University of Oklahoma Health Sciences Center.
Over the course of 5 years, TEALS will:
- Conduct focus groups and semi-structured interviews with CNHSA patients, clinicians, and health administrators to elucidate individual- and system-level barriers and facilitators that affect the implementation of LCS;
- Develop an LCS care coordination intervention that will identify eligible persons for LCS, help these patients navigate the screening process, and link them with smoking cessation services, when applicable;
- Measure the impact of the TEALS intervention on the receipt of screening and a set of patient- and practice-level outcomes by conducting a cluster-randomized clinical trial of LCS implementation; and
- Disseminate the TEALS program to other researchers and healthcare systems that serve AI/AN patients. TEALS will bridge the gap between evidence and clinical practice for LCS in a high-need, low-resource setting by intervening at the level of the healthcare system.
System-level interventions for guideline implementation tend to be understudied compared to those evaluating individual-level, behavioral interventions. However, the careful development and evaluation of an LCS screening program at the level of the healthcare system would be critical to ensure that more patients can receive LCS. Our research will create a critically needed platform from which future studies could be launched that will examine how to tailor the application of the LCS guideline to the individual preferences of AI/AN patients.
TEALS will establish an effective LCS program in a tribal system and thus provide a direct benefit to the Choctaw Nation by increasing LCS participation. TEALS will serve as a blueprint for establishing a sustainable and accessible infrastructure for LCS in AI/AN and other community health systems. By increasing screening for early stage lung cancer, TEALS could ultimately reduce lung cancer mortality in AI/AN communities.
Detailed description
Lung cancer screening (LCS) with low-dose computed tomography (LDCT) reduces mortality from lung cancer and it is recommended by the United States Preventive Services Task Force (USPSTF) based on grade-B evidence, 1 the same grade of evidence given by the USPSTF for breast cancer screening with mammography. Lung cancer is the leading cause of cancer death among American Indians and Alaska Natives (AI/AN),2-4 who face persistent disparities in lung cancer incidence, stage of diagnosis, stage-specific survival, and death compared to Whites, particularly in the Plains states and Alaska.2,3,5-14 Early detection of lung cancer at less lethal stages would have a significant impact on improving the health of Native Americans by reducing their lung cancer mortality. In addition to detection and treatment, smoking cessation is also pivotal to improving lung cancer outcomes.
LCS implementation at the healthcare system level is complex15 and uptake has been slow for the general population, particularly in community settings. System-level implementation may be even more complex in AI/AN communities, which are often characterized by distinctive community, cultural, and health system factors. Community-based participatory research, founded on a partnership approach to research that involves community members, organizational representatives, and researchers in all aspects of the research process,16 has improved research partnerships with AI/AN communities,17 including cancer related research.18-22 Moreover, dissemination and implementation (D\&I) science23-25 has been highly effective in redesigning care delivery systems to improve the uptake of preventive services,25 but has received scant attention in LCS implementation or in AI/AN communities. Coupling the principles of participatory research with D\&I science holds great promise for developing a durable and novel LCS program that responds to the needs of patients, communities, and healthcare systems.
The Choctaw Nation, the third largest tribe in the nation by population, is located in rural southeastern Oklahoma. The advent of the LCS guideline prompted the tribe to name LCS as a top priority for its own, tribally operated healthcare system, the Choctaw Nation Health Services Authority (CNHSA). An ensuing partnership-based consultation over the past several years between CNHSA staff and university researchers with expertise in D\&I science, led to the present study entitled "Tribally Engaged Approaches to Lung Screening (TEALS)". The goal of TEALS is to collaboratively co-develop, implement and evaluate a sustainable and community-centered LCS implementation program that can be disseminated to other tribal health systems.
Our specific aims are to:
Aim 1. Identify individual, community, cultural, and health system barriers and facilitators that affect LCS implementation in the Choctaw Nation. During Year 1, the investigators will convene focus groups and administer semi-structured interviews with key stakeholders (tribal members receiving care through CNHSA, tribal community leaders, clinicians, and health administrators) to elucidate individual, tribal, cultural and health system factors that may critically affect the uptake of LCS. The investigators will incorporate our findings into the TEALS intervention protocols and materials.
Aim 2. Use community-engagement processes to co-design a tailored TEALS intervention, which features LCS care coordinators embedded within the CNHSA healthcare delivery system. In Year 2, informed by Aim 1 findings, the investigators will finalize the TEALS intervention, and then pilot test, evaluate, and iteratively improve it in two CNHSA primary care practices.
Aim 3. Measure the impact of the improved LCS program in a cluster-randomized clinical trial, assessing implementation process outcomes at the individual and care delivery system level. In Years 3 and 4, the investigators will conduct a pair-matched, cluster-randomized implementation trial of the LCS program in three control and three intervention primary care CNHSA practices. The investigators hypothesize that a significantly higher proportion of LCS-eligible patients in the intervention group will receive LCS, and significantly more LCS participants who smoke cigarettes in the intervention group will be referred for smoking cessation advice, compared to the control group.
Aim 4. Disseminate the LCS program to other health systems serving AI/AN patients. In Year 5, the investigators will work closely with Choctaw Nation and other AI/AN-serving health system stakeholders in Oklahoma and other US locations to disseminate the TEALS program in order to facilitate the replication of the program in other settings.
Our team shares the commitment to engage in research that is of direct benefit to AI/AN communities. The national rate of LCS with low-dose CT was only 3.9% in 2015, 26 making this project particularly timely and relevant. TEALS will provide immediate benefit in rates of lung cancer screening for the Choctaw Nation, and has the ultimate goal of reducing lung cancer mortality by widespread implementation of LCS in health systems serving AI/AN communities. TEALS has the novel feature of combining participatory approaches with implementation science to create one of the first systematically designed and tribally run LCS programs in the country. Incorporating feedback from tribal community members and patients as well as healthcare professionals will enable an iterative adaptation of the TEALS intervention to the needs of healthcare systems serving Native people. Our participatory approach to D\&I science will provide an exemplary means of optimizing dissemination and implementation of LCS in other healthcare settings serving AI/AN patients.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 7
- Model description
- Pair-matched cluster-randomized controlled implementation trial with delayed intervention in the control group
| Arm | Type | Receives |
|---|---|---|
| Control 1-1 | Experimental | Other: Enhanced lung cancer screening servicesPatients and clinicians in control practices will receive usual Electronic Health Record (EHR) reminders for lung cancer screening (LCS). |
| Intervention 1-1 | Experimental | Other: Enhanced lung cancer screening servicesIn addition to control group improvements, patients and clinicians in the intervention group will also receive an LCS Care Coordinator. |
| Control 1-2 | Experimental | Other: Enhanced lung cancer screening servicesPatients and Clinicians in control practices will have access to existing LCS services, smoking cessation, and lung cancer treatment services, but no additional system improvements will be introduced. |
| Intervention 1-2 | Experimental | Other: Enhanced lung cancer screening servicesIn addition to control group improvements, patients and clinicians in the intervention group will also receive quality of care benchmarking and feedback academic detailing. |
| Intervention 1-3 | Experimental | Other: Enhanced lung cancer screening servicesIn addition to control group improvements, patients and clinicians in the intervention group will also receive practice facilitation. |
| Intervention 1-4 | Experimental | Other: Enhanced lung cancer screening servicesIn addition to control group improvements, patients and clinicians in the intervention group will also receive the opportunity to participate in a learning collaborative. |
| Intervention 1-5 | Experimental | Other: Enhanced lung cancer screening servicesIn addition to control group improvements, patients and clinicians in the intervention group will also receive information technology support. |
Who may qualify
- Ages
- 50 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- adults aged 50-80
- 30 pack-year smoking history
- currently smoke or quit in the past 15 years.
Key exclusion criteria (2 listed)
- Those who are not willing to be screened or followed up with diagnostic testing or intervention, if positive.
- Those who are otherwise designated by their primary care doctors as not able to benefit from screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Enhanced lung cancer screening servicesAlso: LCS interventionA theoretically sound and evidence-based, multi-component implementation strategy will be applied which includes care quality benchmarking and regular performance feedback, academic detailing provided by specially trained primary care clinicians, practice facilitation provided by trained and certified Practice Facilitators (PFs), health information technology (HIT) support, and facilitated professional networking to promote the cross-pollination and rapid dissemination of solutions and best practices in primary care settings | Other | Control 1-1, Control 1-2, Intervention 1-1, Intervention 1-2, Intervention 1-3, Intervention 1-4, Intervention 1-5 |
Primary outcome
1. Uptake of low-dose computed tomography lung cancer screening services
Time frame: 12 months
Receiving lung cancer screening (LCS) when eligible
2. Uptake of low-dose computed tomography lung cancer screening services
Time frame: 12 months
Participating in a care planning visit with the lung-cancer screening coordinator (LCC) before screening and a follow-up visit, if screened positive
3. Uptake of low-dose computed tomography lung cancer screening services
Time frame: 12 months
Receipt of follow-up treatment when clinically recommended
4. Uptake of low-dose computed tomography lung cancer screening services
Time frame: 12 months
Receipt of smoking cessation intervention at any point of the LCS process.
1. Health system-level care process outcomes
Time frame: 12 months
A RE-AIM framework will be utilized. Reach of the screening program will be measured by the proportion of LCS-eligible patients who were contacted by the screening coordinator
2. Health system-level care process outcomes
Time frame: 12 months
A RE-AIM framework will be utilized. Effectiveness will be measured by the proportion of eligible patients who have completed the screening and treatment process according to their particular needs
3. Health system-level care process outcomes
Time frame: 12 months
A RE-AIM framework will be utilized. Adoption will be measured by the proportion of individual clinician practices in the Choctaw Nation healthcare system that implemented the program.
4. Health system-level care process intervention outcomes % of patients with LCS
Time frame: 12 months
A RE-AIM framework will be utilized. Implementation will be measured as the fidelity to the steps of the pre-determined LCS process in each practice
5. Health system-level care process improvement outcomes
Time frame: 12 months
A RE-AIM framework will be utilized. Maintenance will be measured as the time of sustaining each LCS implementation key component at the practice and system level.
13 secondary outcomes
Patient and health system-level scales
Time frame: 12 months
CAHPS
Time frame: 12 months
PAM
Time frame: 12 months
CPCQ
Time frame: 12 months
ACIC
Time frame: 12 months
Qualitative measures of barriers and facilitators of patient participation in TEALS
Time frame: 12 months
Qualitative measures of barriers and facilitators of patient participation in TEALS
Time frame: 12 months
Qualitative measures of barriers and facilitators of patient participation in TEALS
Time frame: 12 months
Qualitative measures of barriers and facilitators of patient participation in TEALS
Time frame: 12 months
Qualitative measures of barriers and facilitators of practice participation in TEALS
Time frame: 12 Months
Qualitative measures of barriers and facilitators of practice participation in TEALS
Time frame: 12 Months
Qualitative measures of barriers and facilitators of practice participation in TEALS
Time frame: 12 Months
Qualitative measures of barriers and facilitators of practice participation in TEALS
Time frame: 12 Months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Apr 2026.
- Individual participant dataSharing planned: No. Sharing of IPD is strictly sanctioned by tribal health organizations. For this reason IPD will not be shared with entities not involved in the research activities.
Related trials for Lung Cancer
Recruiting
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
Lung Neoplasms, Neoadjuvant Therapy
Not yet recruitingPhase 3
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (Icc)
Active, not recruitingPhase 3
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
Non-small Cell Lung Cancer Stage IV
RecruitingObservational study
Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.
Lung Cancer
RecruitingPhase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Enhanced lung cancer screening services in people with Lung Cancer, run by University of Oklahoma at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 1 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
1. Uptake of low-dose computed tomography lung cancer screening services (time frame: 12 months). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2026.